U.S. Capital Markets Stock News

NasdaqGS:IREN
NasdaqGS:IRENSoftware

3 Stocks Estimated To Be Up To 46.5% Below Intrinsic Value

In recent days, major U.S. stock indexes have experienced sharp declines, with technology shares leading the downturn amid concerns about high valuations and broader market volatility. As investors navigate these turbulent times, identifying undervalued stocks can be an effective strategy for those seeking to capitalize on potential market inefficiencies. Understanding intrinsic value is crucial in this environment, as it allows investors to assess whether a stock is trading below its true...
NasdaqGS:PCB
NasdaqGS:PCBBanks

November 2025's Top Dividend Stocks To Consider

As of early November 2025, major U.S. stock indexes have experienced a sharp decline, with technology stocks leading the downturn amid broader market volatility and ongoing economic uncertainties such as the prolonged government shutdown. In this environment, dividend stocks can offer a degree of stability and income potential for investors seeking to navigate these turbulent times by focusing on companies with strong fundamentals and consistent dividend payouts.
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Madrigal Pharmaceuticals (MDGL): Forecasts Point to 34.8% Annual Revenue Growth Ahead of Earnings

Madrigal Pharmaceuticals (MDGL) remains in the red, with losses widening at a 15.3% annual rate over the last five years and net profit margins not improving in that period. Looking ahead, analysts forecast annual revenue growth of 34.8% and earnings growth of 67.2% per year, setting the company on a path to profitability within three years. This represents a much faster trajectory than the US market’s projected 10.5% revenue growth. With shares trading below an estimated fair value and the...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Halozyme Therapeutics (HALO) Profit Margin Jumps to 47.9%, Reinforcing Bullish Narratives

Halozyme Therapeutics (HALO) posted net profit margins of 47.9%, a significant jump from last year’s 41.4%, as earnings growth for the year hit 51.7%. This figure is twice its five-year average of 20.8% per year. Looking ahead, analysts expect earnings and revenue to continue rising by around 11.6% annually. The company’s price-to-earnings ratio of 13.4x sits comfortably below both the US biotech average of 16.9x and peers at 19.6x. Investors are eyeing the combination of strong...
NasdaqGM:AUPH
NasdaqGM:AUPHBiotechs

Aurinia Pharmaceuticals (AUPH): Profitability Flips, Outpacing Market Growth Expectations and Reinforcing Bullish Narratives

Aurinia Pharmaceuticals (AUPH) has flipped to profitability after five years of transformation, posting average annual earnings growth of 43.8%. Forward guidance points to EPS growth of 17.13% per year and revenue growth of 12.5% per year, both topping the US market average of 10.5%. Improving net profit margins and high-quality earnings continue to shape investor sentiment heading into the latest results. See our full analysis for Aurinia Pharmaceuticals. Next, we will see how these...
NYSE:TAP
NYSE:TAPBeverage

Molson Coors (TAP): Loss Reductions and Earnings Growth Forecast Challenge Bearish Narratives

Molson Coors Beverage (TAP) is forecast to turn profitable within the next three years, with projected earnings growth of 65.59% annually. Revenue, however, is expected to rise just 0.6% per year, well below the US market average of 10.5%. While the company remains unprofitable in the latest results, losses have declined at an annual rate of 17.4% over the past five years. At $43.67 per share, TAP trades at a price-to-sales multiple of 0.8x, below both peer and sector averages, and notably...